Pfizer's India unit posts higher Q1 profit and revenue; EBITDA margin widens
AI Market Summary
Pfizer's India unit reported solid Q1 FY2024 results, with net profit and revenue rising year over year and EBITDA margin expanding, prompting a modest post-earnings share uptick. As a single-company earnings release, the information is primarily idiosyncratic and should have limited spillover to broader risk sentiment or cross-asset positioning in the near term.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-1.39%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Pfizer Ltd., Pfizer's listed subsidiary in India, reported results for the first quarter of fiscal 2024. Net profit rose 6.7% year on year to 20.5 billion Indian rupees, while operating revenue increased 8.3% to 65.3 billion rupees. EBITDA climbed 18% to 24.8 billion rupees, lifting the EBITDA margin to 38% from 35%. Following the release, the company's shares gained 0.47% to 4,712.05 rupees. The update relates to a single listed entity and had a direct impact on its own share price.
